Trevi Therapeutics (TRVI) News Today

Wall Street analysts see big potential upside for small-cap biopharma firm Trevi Therapeutics. So, what does the firm do and how does it stand out?

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 10,981 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the sale, the chief executive officer now owns 213,313 shares of the company's stock, valued at approximately $644,205.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has earned an average rating of "Buy" from the six research firms that are covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The av

Raymond James assumed coverage on Trevi Therapeutics in a research note on Friday. They set an "outperform" rating and a $9.00 price target for the company.

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) Director David P. Meeker sold 4,555 shares of the business's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $2.93, for a total value of $13,346.15. Following the completion of the sale, the director now directly owns 352,489 shares in the company, valued at $1,032,792.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

EF Hutton Acquisition Co. I upgraded Trevi Therapeutics to a "strong-buy" rating in a research report on Monday.

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) insider Thomas Sciascia sold 18,660 shares of the business's stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the sale, the insider now owns 220,315 shares of the company's stock, valued at approximately $608,069.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Research analysts at B. Riley dropped their Q3 2024 EPS estimates for Trevi Therapeutics in a report issued on Tuesday, August 13th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings of ($0.09) per share for the qu

Trevi Therapeutics (NASDAQ:TRVI) will be releasing earnings after the market closes on Thursday, August 8, Zacks reports.

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 1,270,000 shares, an increase of 32.6% from the June 30th total of 957,600 shares. Based on an average daily trading volume, of 225,000 shares, the days-to-cover ratio is currently 5.6 days.

Opaleye Management Inc. lifted its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 48.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,535,000 shares of the company's stock after buyi

Frazier Life Sciences Management L.P. raised its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 7.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,381,090 shares of the company's stock after buying an additional 500,00

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 25,037 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $2.86, for a total value of $71,605.82. Following the completion of the sale, the chief executive officer now owns 213,313 shares of the company's stock, valued at approximately $610,075.18. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 4,578 shares of the company's stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $2.90, for a total value of $13,276.20. Following the transaction, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at $618,607.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link.